In Re Access Cardiosystems, Inc.

361 B.R. 626, 2007 Bankr. LEXIS 472, 2007 WL 495160
CourtUnited States Bankruptcy Court, D. Massachusetts
DecidedFebruary 16, 2007
Docket14-11149
StatusPublished
Cited by2 cases

This text of 361 B.R. 626 (In Re Access Cardiosystems, Inc.) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Access Cardiosystems, Inc., 361 B.R. 626, 2007 Bankr. LEXIS 472, 2007 WL 495160 (Mass. 2007).

Opinion

MEMORANDUM OF DECISION

HENRY J. BOROFF, Bankruptcy Judge.

Before the Court is the “Debtor’s Omnibus Objection to General Unsecured *629 Claims Asserted by European Distributors” (the “Objection” or “Objection to Claims”) filed by Access Cardiosystems, Inc. (the “Debtor”). The Objection and various supplementary memoranda filed by the Debtor and the claimants raise several issues of contract law and interpretation. The Debtor asks this Court to disallow the claims in their entirety as foreclosed by various provisions of agreements between the Debtor and the claimants. The claimants, in turn, ask this Court to conduct an evidentiary hearing to determine factual issues regarding the Debtor’s alleged breach of the contracts and the amount of damages resulting from that breach.

I. FACTS AND TRAVEL OF THE CASE

A. The Distribution Agreements

The present controversy arises from several distribution agreements (the “Agreements”) executed by the Debtor and various European distributors 1 (the “Distributors”) during the latter part of 2001 and the early part of 2002, several years prior to the filing of the instant Chapter 11 bankruptcy case. Under the Agreements, the Distributers were granted exclusive rights to market and sell the Debtor’s automated external defibrillators (“AEDs” or “Access AEDs”) 2 within their respective territories throughout Europe. 3

Section 3 of the Agreements detailed various obligations of the Distributors, including promotion, marketing, minimum commitments and training criteria. In addition, under Section 3.17, except as otherwise provided or agreed to in writing by the Debtor and a Distributor, the Distributors bore “all costs and expenses incurred in the performance of Distributor’s obligations under th[e] Agreement^].” In return, the Distributors each received a limited license of the Debtor’s intellectual property rights to sell the AEDs exclusively within their respective European territories.

The initial term of each Agreement was two years, unless terminated pursuant to Section 11. Under Section 11.2, either party could terminate the Agreement for cause, 4 and under Section 11.3, either par *630 ty could terminate the Agreement with or without cause, provided that written notice was given of the termination six months prior to the effective date of the termination. The Agreement further limited liability with respect to terminations under Section 11 of the Agreement. 5

Each Agreement also disclaimed all warranties relative to the Access AEDs, with the exception of limited warranties extended to the ultimate end-users of the product. 6 In addition to excluding warranties, Section 15 of the Agreements also limited the parties’ liability in the event of breach:

15. LIMITED LIABILITY
15.1 Limitations and Exclusions. REGARDLESS OF WHETHER ANY REMEDY SET FORTH HEREIN OR ACCESS CARDIOSYSTEMS’S LIMITED WARRANTY ACCOMPANYING DELIVERY OF THE ACCESS CARDIOSYSTEMS PRODUCT
FAILS OF ITS ESSENTIAL PURPOSE OR OTHERWISE, NEITHER PARTY WILL BE LIABLE FOR ANY LOST PROFITS OR FOR ANY INDIRECT, INCIDENTAL, CONSE *631 QUENTIAL, PUNITIVE OR OTHER SPECIAL DAMAGES SUFFERED BY DISTRIBUTOR, ITS CUSTOMERS OR OTHERS ARISING OUT OF OR RELATED TO THIS AGREEMENT OR THE ACCESS CARDIOSYSTEMS PRODUCT, FOR ALL CAUSES OF ACTION OF ANY KIND (INCLUDING TORT, BREACH OF CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY) EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
15.2 Maximum Aggregate Liability. IN NO EVENT WILL ACCESS CAR-DIOSYSTEMS’S TOTAL CUMULATIVE LIABILITY IN CONNECTION WITH THIS AGREEMENT OR THE ACCESS CARDIOSYSTEMS PRODUCT, FROM ALL CAUSES OF ACTION OF ANY KIND, INCLUDING TORT, BREACH OF CONTRACT, NEGLIGENCE, STRICT LIABILITY AND BREACH OF WARRANTY, EXCEED THE TOTAL AMOUNT PAID BY DISTRIBUTOR TO ACCESS CAR-DIOSYSTEMS HEREUNDER.
15.3 Acknowledgment. Distributor agrees that the limitations of liability and disclaimers of warranty set forth in this Agreement are independent of any remedies hereunder and apply regardless of whether any remedy fails of its essential purpose. Distributor acknowledges that Access CardioSystems has set its prices and entered into this Agreement in reliance on the disclaimers of liability, the disclaimers of warranty and the limitations of liability set forth in this Agreement and that the same form an essential basis of the bargain between the parties.

Given the nature of the AEDs and the regulations imposed by the United States Food and Drug Administration (the “FDA”), it is unsurprising that the Agreements also contained provisions regarding the parties’ rights and obligations in the event of a recall. The relevant provisions of Section 9 of the Agreements provide:

9.2 Notification by Access CardioS-ystems. If a product investigation by a party or government office or agency results in a potential product recall or correction of the Access Cardiosystems Product, Access CardioSystems shall retain full authority and responsibility for decisions on such recall or correction. If Access CardioSystems decides to conduct a recall or correction, Access Car-dioSystems will provide written notice to Distributor within twenty-four (24) hours of such decision, and a summary of the reason for and implementation of such action. Access CardioSystems shall provide such information as Distributor may reasonably require to prepare any additional customer notification of such recall or correction, which notification shall be issued by Distributor.
9.3 Procedure. Any such recall, correction or notification shall be handled in accordance with the recall, correction and customer notification policy and procedures maintained by Access Cardiosystems. Access CardioSystems shall promptly reimburse all reasonable, necessary and documented costs for any recall of the Access CardioSystems Product that are incurred by Distributor with the prior approval of Access Car-dioSystems. 7

*632 B. The Recall

In October of 2004, the Debtor learned of potential problems with the AEDs that eventually led to the issuance, on November 3, 2004 of its “Urgent Recall Notice” (the “Recall Notice”). The Recall Notice was mailed to customers and the Distributors, and provided:

URGENT RECALL NOTICE-IMMEDIATE ACTION REQUIRED
Access CardioSystems, Inc.’s Access AED and AccessALS Automated External Defibrillators
November 3, 2004

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Bh S & B Holdings LLC
426 B.R. 478 (S.D. New York, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
361 B.R. 626, 2007 Bankr. LEXIS 472, 2007 WL 495160, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-access-cardiosystems-inc-mab-2007.